Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P130017/S066

Cologuard

Exact Sciences Corporation · Decision date Nov 24, 2025

FDA DECISIONP130017/S066

What did the FDA approve?

FDA records P130017/S066 as a supplement to PMA P130017, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Nov 24, 2025.

FDA approval order statement

The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) supplement, which qualified for review under the Real-Time Review Program. Your supplement requested to modify the in-process sample stability of the hemoglobin sample from 7 days to 14 days at 2 to 8°C, and additional minor labeling changes. Based upon the information submitted, the PMA supplement is approved. You may begin commercial distribution of the device as modified by your PMA supplement in accordance with the conditions described below. Although this letter refers to your product as a device, please be aware that some approved products may instead be combination products.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Pathology
Decision date
Nov 24, 2025
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P130017/S066
Regulatory pathway
PMA supplement
Product code
PHP
Decision code
APPR
Decision date
Nov 24, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: System, colorectal neoplasia, DNA methylation and hemoglobin detection.

Product code
PHP
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P130017/S066 received

    Application receipt date recorded by FDA.

  2. P130017/S066 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P130017. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P130017

Product / regulatory recordCompanyPathwayDecision dateSource
CologuardP130017/S063
Exact Sciences CorporationPMA supplementJul 18, 2025FDA
Cologuard testP130017/S064
Exact Sciences CorporationPMA supplementJul 24, 2025FDA
CologuardP130017/S065
Exact Sciences CorporationPMA supplementOct 7, 2025FDA
CologuardP130017/S067
Exact Sciences CorporationPMA supplementMar 13, 2026FDA
CologuardP130017/S069
Exact Sciences CorporationPMA supplementApr 22, 2026FDA
CologuardP130017/S068
Exact Sciences CorporationPMA supplementMay 27, 2026FDA
CologuardP130017/S070
Exact Sciences CorporationPMA supplementJun 9, 2026FDA

Explore the linked device profile

Other records with product code PHP

Product / regulatory recordCompanyPathwayDecision dateSource
SimpleScreen CRCP250029/S003
Freenome, LLCPMA supplementOct 27, 2026FDA
ShieldP230009/S021
Guardant Health, Inc.PMA supplementOct 5, 2026FDA
ShieldP230009/S020
Guardant Health, Inc.PMA supplementSep 16, 2026FDA
SimpleScreen CRCP250029/S001
Freenome, LLCPMA supplementAug 26, 2026FDA
Cologuard PlusP230043/S010
Exact Sciences CorporationPMA supplementAug 3, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Exact Sciences Corporation

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
441 Charmany Dr., Medison, WI, 53719

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records